Help Wanted for the Quest!
Completed: 0%
Quest hub:
Screening, detection, diagnosis, and monitoring of Cancer. Striving for early, accurate, safe and cost effective methods.
Welcome new Heroes (including all user testers)!
Visitors, explore and click the tabs from DATA to EVENTS (scroll left on mobile)
What is our purpose with this Quest?
- To create agile, interactive, and complete overviews and roadmaps of the science and technologies driving progress on early, accurate, safe, easy, and cost effective Cancer screening and diagnostic methods, and then help accelerate that progress
How?
- The publicly available databases and roadmaps we create as a community help align all entities working on solutions and identify where to focus efforts and resources for maximum impact
- Enable anyone, even non-technical people, to take action on this disease with science, technology, and innovation via our tasks
- Provide an open source pre-projecting platform to nurture ideas and breed innovation for new and improved solutions
- This all leads to making the most of our global resources, collaboration, and impact to accelerate progress on the ideal solutions
Want to help?
- Become a Hero and JOIN NOW (is free, takes 5-10 minutes here and there to do digital volunteering Tasks)
- Spread the word: follow, like, tag, share! Insta LinkedIn FB Twitter YouTube
- Show some love with donations via our Support page
Volunteering Heroes, go take action with a Task, be vocal in the Labs, or post in the newsfeed!
Current Quest objective: Let's find 21 EVENTS this year (objective ends February 5, 2021)
Expand the "Completed:" progress bar above for more details on how to help with this
Read our Quest community written article on...
Check out our intro and overview...
Quest leaderboard
Feb 10, 2021
The illuminating new “light pollution” study was published Monday in the American Cancer Society journal, Cancer.
Feb 10, 2021
When treating cancer, researchers are always searching for ways to remove cancer cells while minimizing damage to the rest of the body. One possible approach is to find processes unique to cancer cells, and which would allow specific targeting. If such a process can be disrupted, only those cells would be affected. Professor Tomer Shlomi’s research group discovered such a process.
Feb 10, 2021
Targeting and changing autophagy, otherwise known as cell recycling, has been linked to helping control or diminish certain cancers. Now, University of Cincinnati researchers have shown that completely halting this process in a very aggressive form of breast cancer may improve outcomes for patients one day.
Jan 31, 2021
Cancer screenings have dropped between 86% and 94% in preventive cancer screenings nationwide, compared to 2017 to 2019.
Jan 29, 2021
Gene mutations associated with breast cancer even in women who do not have a history of the disease offer a new way of estimating risk and may lead to future changes screening and management.
Jan 28, 2021
Jan 15, 2021
Screening for skin cancer should stop, as it is contributing to an overdiagnosis of melanoma, say NEJM authors, but the issue is nuanced, retort melanoma experts.
Nov 12, 2020
The parties signed a multi-target exclusive licensing agreement for application of Cherry Biolabs' Hemibody technology. This Hemibody technology, in combination with MorphoSys' antibody know-how and technologies, offers the potential to generate novel T-cell engaging medicines with higher precision and better safety profiles for the treatment of cancer patients
Nov 12, 2020
Pioneering research conducted by University of Virginia and APIS Assay Technologies demonstrates Hormone-Upregulated lncRNA within lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples.
Nov 12, 2020
November 11, 2020 — Digital breast tomosynthesis (DBT), in combination with synthetic mammography, improves cancer detection over digital mammography alone, according to a study from Italy published in the journal Radiology.
Nov 07, 2020
Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system's T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.
Nov 07, 2020
The Radixact System is capable of treating virtually any radiation therapy indication, including breast, lung, prostate and head and neck cancers, in addition to complex cases such as total marrow irradiation, providing more patients with the opportunity to benefit from the fast, highly precise radiation treatments it delivers.